Univercells, RoosterBio Partner to Optimize Manufacturing of Extracellular Vesicles

Univercells Technologies, a provider of novel biomanufacturing technologies for flexible and scalable viral production, has entered a strategic partnership with RoosterBio Inc., a supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and hMSC bioprocess systems. This partnership will optimize manufacturing of extracellular vesicles (EVs) using scalable and continuous bioprocessing technologies to propel the commercialization of regenerative therapies at affordable costs.
 
The goal is to deliver complete solutions for exosomes manufacture, leveraging Univercells Technologies’ intensified and integrated platforms and RoosterBio’s hMSC bioprocess and highly engineered media systems. As part of the partnership, RoosterBio will establish EV production process using their hMSCs from microcarriers in the scale-X hydro fixed-bed bioreactor which features 2.4 m² surface for cell growth. Following initial optimization to confirm cell growth, productivity, and product quality, Univercells Technologies and RoosterBio will collaborate in the development of a continuous process in perfusion mode. Through the use of intensified and integrated technologies, this joint effort will enable developers to accelerate timelines, reduce costs, and manufacture their regenerative therapies via a scalable, commercially viable platform.
 
”We are continuously seeking disruptive technologies to expand the impact of our innovative hMSC and EV products and bioprocess solutions,” stated Tim Kelly, CEO of RoosterBio. “Together, Univercells Technologies and RoosterBio will leverage our novel technologies and expertise to accelerate our customers’ journey from preclinical development to commercialization, reducing complexity and costs to make these life-saving therapies accessible for all patients.”
 
“Exosomes have emerged as a promising technology for advanced therapies such as viral vaccines and gene therapies. We are proud to partner with RoosterBio to demonstrate how purposefully designed technologies such as the scale-X bioreactor portfolio can enable the rapid delivery of reliable and affordable regenerative therapies,” says Mathias Garny, CEO of Univercells Technologies.
 
Both companies will look into extending this study among the scale-X carbo bioreactor (10 and 30 m² growth surface) with integrated in-line product concentration enabling continuous exosomes manufacturing.